Projeted Growth

Growth Potential Meter

Urological Cancer Therapeutics Drugs Market by Product Type (Xofigo (radium Ra 223 dichloride), Jevtana (cabazitaxel), Inlyta (axitinib),Votrient (pazopanib hydrochloride), Sutent (sunitinib malate),Zytiga (abiraterone acetate), Xtandi (enzalutamide), Opdivo (nivolumab), Provenge (sipuleucel-T)) by Application /End User(Hospital, Medical Research Laboratory) by Industry Analysis, Volume, Share, Growth, Challenges, Trends, and Forecast 2017

Number of pages: 116 | Report Code: PSMR- PSMR-20064 | Report Format : PDF

Report Coverage

Parameters Details

Base Year


Historical Data


Forecast Data


Base Year Value (2021)

USD million

Forecast Value (2028)

USD million

CAGR (2022 to 2028)


Regional Scope

North America, Europe, Asian Pacific, Latin America, Middle East and Africa, and ROW

Global Urological Cancer Therapeutics Drugs Market is estimated to reach USD 53.65 billion by 2026, growing at a CAGR of 10.5 % between 2018 and 2026  

Now a days urological cancers became very common worldwide and causing higher mortality rates. Specially in the case of kidney cancers, that illustrates the new therapeutic targets. Urological cancers accounts for approximately 20% of global cancer prevalence. This type of cancer affects the urinary tract of male and female and the male reproductive organs. In male prostate cancer is more common of these malignancies. Basically in urological cancer there is the growth of abnormal tissues in bladder, prostate, penile, testicular or kidney. This abnormal growth of tissues is referred to as tumours, which even spreads into the surrounding tissues or muscles.  

The urological cancer market is segmented into cancer type, treatment type, end-user, and geography.There are different types of urological cancers such as kidney, prostate, testicular and bladder cancer. On the basis of type of treatment, the market is divided into chemotherapy, hormonal therapy, and surgery & radiation therapy. Depending on end-user, the market is divided into hospitals, urological cancer medical research laboratory and others. Top players of this market are Novartis, Pfizer, Johnson & Johnson, Astra Zeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, GlaxoSmithKline plc, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare and Sanofi S.A.  

Geographically, Global Urological Cancer Therapeutics Drugs market is classified as North America, Europe, Southeast Asia , China, Japan and India. Currently, North America dominates the urological cancer market because of increasing geriatric population, available advanced health care solutions, new product innovations, well developed healthcare infrastructure and technological advancements. North America is followed by Europe due to research and development activities and at the same time increasing consumption of alcohol and smoking behaviour.  

Global Urological Cancer Therapeutics Drugs Market

Urological Cancer Therapeutics Drugs Market : Product Type

  • Xofigo (radium Ra 223 dichloride)
  • Jevtana (cabazitaxel)
  • Inlyta (axitinib)
  • Votrient (pazopanib hydrochloride)
  • Sutent (sunitinib malate)
  • Zytiga (abiraterone acetate)
  • Xtandi (enzalutamide)
  • Opdivo (nivolumab)
  • Provenge (sipuleucel-T)

Urological Cancer Therapeutics Drugs Market : Application

  • Hospital
  • Medical Research Laboratory

Global Urological Cancer Therapeutics Drugs Market: Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Global Urological Cancer Therapeutics Drugs Market:

  • Novartis
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • Astellas
  • Bristol-Myers Squibb
  • Abbott Laboratories
  • Celgene Corporation
  • Dendreon Corporation
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Indevus Pharmaceuticals Inc
  • Ipsen
  • Roche Healthcare
  • Sanofi S.A.

Geographical analysis of Urological Cancer Therapeutics Drugs Market:

  • North America
    • U.S.A
    • Canada
  • Europe
    • France
    • Germany
    • Spain
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South East Asia
  • Latin America
    • Brazil
  • Middle East and Africa

Urological Cancer Therapeutics Drugs Market Report delivers comprehensive analysis of :

  • Market Forecast for 2018-26
  • Market growth drivers
  • Challenges and Opportunities
  • Emerging and Current market trends
  • Market player Capacity, Production, Revenue (Value)
  • Supply (Production), Consumption, Export, Import analysis
  • End user/application Analysis

Frequently Asked Questions (FAQ)

Urological Cancer Therapeutics Drugs Market was valued at around USD million in 2021 & estimated to reach USD by 2028.

Urological Cancer Therapeutics Drugs Market is likely to grow at compounded annual growth rate (CAGR) of % between 2022 to 2028.

Yes, the report includes COVID 19 impact on the market.

  Download Sample

Please fill below details:


    Select Licence Type

      Single User -          $2550

      Corporate User -   $3550

    Urological Cancer Therapeutics Drugs Market Covid 19 Impact Analysis
    Why Profshare?

      High Data Accuracy

    Precise research methodology, numerous analysis models & up to date data resources to achive most accurate market values.

     Customization as Needed

    We can tailored the report as per your requirments & budget, Most of our clients prefer custom reports.

      Budget Friendly Solution

    We have quality market data for all types of budget & so now get best out of your market research budget.

      Quality Support

    Be assured of receving satisfactory analyst support to understand research report in-detail.